. The challenges of receiving and delivering this novel therapy were discussed at the NCCN 2019 Annual Conference’s keynote session. In a separate roundtable discussion, additional stakeholders discussed how payers and providers are grappling with the
of care, Dr. Jonasch admitted that anti-VEGF therapy is not a “magic bullet.” VEGF blockade is important but certainly not sufficient, he added, opening the door for novel therapies in RCC. Among the more promising options, the focus is on new cancer
Alvin R. Cabrera, Kyle C. Cuneo, James J. Vredenburgh, John H. Sampson, and John P. Kirkpatrick
the development of novel therapies. Antiangiogenesis has been an active area of investigation, because GBM is among the most angiogenic of malignancies. High-grade gliomas overexpress vascular endothelial growth factor (VEGF), resulting in a dense
Andrew J Klink, Bruce Feinberg, Frank Xiaoqing Liu, Sama Ahsan, Damion Nero, and Bartosz Chmielowski
Background: The treatment (tx) landscape for patients (pts) with metastatic melanoma (MM) has changed dramatically from systemic chemotherapy (chemo) to novel therapies, including targeted therapies (TT) and immunotherapies (IO mono- and
Khalid Mamlouk, Zach Crouch, Philina Lee, Clive Mendonca, Maria Gumina, and Brian Rubin
needed about the role of mutational testing in GIST to ensure optimal treatment, especially among U.S. community oncology practitioners. The data also highlight the need for novel therapies that are effective in PDGFRα D842V-driven GIST.
Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris
, aggressive nature, and limited therapy has made ATC a therapeutic challenge. As a result, the urgent need to identify new and novel therapies for advanced ATC cannot be overemphasized. Identification of molecular aberrations that drive tumor growth can help
Rachel A. Bender Ignacio, Lilie L. Lin, Lakshmi Rajdev, and Elizabeth Chiao
safety and efficacy of other novel therapies for HIV-associated lymphoma, including short-course EPOCH (etoposide/prednisone/vincristine/cyclophosphamide/doxorubicin) and the addition of ibrutinib in dose-adjusted EPOCH as frontline treatment (NCT00006436
R. Michael Tuttle and R. Leboeuf
Although traditional chemotherapy has yielded disappointing results in the therapy of progressive metastatic thyroid cancer, the recent development of a wide range of novel therapies targeting critical steps in the pathogenesis of thyroid cancer has led to a renewed interest in thyroid cancer clinical trials. This review provides an overview of the pathogenesis of thyroid cancer with particular emphasis on specific molecular targets that can be modulated with these novel agents. The article reviews the results for the small number of thyroid cancer patients included in published therapeutic trials and critically examines patient selection criteria for inclusion in clinical trials. Given the dramatic increase in availability of thyroid cancer clinical trials, all patients with radioactive iodine-refractory, progressive metastatic thyroid cancer should be considered for inclusion in a novel therapy trial.
Effective treatment of advanced soft tissue sarcomas remains challenging, despite more than 30 years of clinical trials with conventional chemotherapy. Although some agents display modest efficacy against soft tissue sarcomas, modifications in the doses and combinations of therapies have not consistently led to significant improvements in response rates or concomitant increase in overall survival. Novel therapies designed to inhibit defined molecular alterations, as exemplified by the use of imatinib in gastrointestinal stromal tumors, have revolutionized the approach to the treatment of sarcomas. As more underlying genetic mechanisms are uncovered, new agents designed to target these lesions will lead to more specific, less toxic, and more effective therapies.
Presenter: Eileen M. O’Reilly
Outcomes in pancreatic cancer are improving. The beneficial effects being achieved with adjuvant and neoadjuvant therapies, and the recent application of molecular profiling, both germline and somatic, are collectively impacting survival. The NCCN Guidelines for Pancreatic Cancer urge clinicians to undertake “agnostic” germline testing for all persons with pancreatic cancer. Fit patients should also be considered for adjuvant therapy with modified FOLFIRINOX (leucovorin, 5-FU, irinotecan, oxaliplatin). Novel therapies that focus on DNA damage repair strategies are proving to be important, but notably several late-stage trials of several other approaches, reported in the last year, proved disappointing.